Although ADAR2 is often described as a tumor suppressor due to its editing of key regulatory transcripts, such as COPA in HCC, which shifts the function of ADAR2 from oncogenic to tumor suppressive by inhibiting the PI3K/Akt/mTOR pathway (88), its role is not universally suppressive across all cancer types. This evidence concerns the gene ADARB1 and hepatocellular carcinoma.